VYNE Therapeutics Inc. (VYNE) Q4 2020 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the Vine Therapeutics conference call to discuss the fourth quarter and full year 2020 financial results and update. At this time, all participants are in a listen-only mode. Following the company's formal remarks, we will open the call for your questions. Please be advised that this call is being recorded at the company's request. I will now turn the call over to Michael Wood at LifeSci Advisors. Please go ahead. Good morning, everyone, and thank you for joining us this morning. Before we begin with formal remarks, let me remind you that some of the information in the press release issued this morning and on this conference call contain forward-looking statements that involve risks, uncertainties, and assumptions that are difficult to predict, including statements, forecasts, and observations regarding future financial and operating performance, impacts of the COVID-19 pandemic on buying, and observations regarding ongoing operating expenses and net revenue. These statements will include observations associated with the commercialization of advocacy consultancy in the United States. They will also include plans and expectations regarding the success, timing, and cost of clinical trials. Words that express and reflect optimism, satisfaction with current progress, prospects and rejections, as well as words such as believe, intend, expect, plan, anticipate, and similar variations identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those contained in such statements. Several factors that could contribute to such differences are described in detail in Vine T...